BSX · Earnings call · 2026Q3T · Full report

Acquisition / Partnership / Divestiture

BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 43 · Surprise 42 · In source text

Boston Scientific expects to close its acquisition of Penumbra in early 2027, subject to remaining regulatory clearances. Management said Penumbra’s portfolio and strategic fit are expected to strengthen the company’s long-term growth profile and complement its cardiovascular business. Boston Scientific also entered an agreement with Blackstone Life Sciences to co-fund development of its Vitalist Circulatory Support System for cardiogenic shock. Blackstone funding will reduce R&D expense as related costs are incurred; starting with expected milestones in 2030, Blackstone may receive a return on amounts funded plus royalties on Vitalist sales.

Key facts

• Boston Scientific entered an agreement with Blackstone Life Sciences to co-fund Vitalist development for cardiogenic shock treatment.
• Boston Scientific will receive Blackstone funding recognized as a reduction to R&D expense as related costs are incurred; upon milestones expected starting in 2030, Blackstone may receive a return on amounts funded plus Vitalist sales royalties.
• Boston Scientific expects to close the Penumbra acquisition in early 2027, subject to remaining regulatory clearances.
• Boston Scientific announced the Penumbra transaction in mid-January and anticipated closing in early 2027.
• At the Penumbra transaction announcement, Boston Scientific expected $0.06 to $0.08 of dilution, assuming no divestiture and the interest rates in place at that time.
• Boston Scientific anticipates an early first-quarter 2027 close of the Penumbra transaction, based on regulatory discussions.
• Boston Scientific said it was bullish on the Penumbra transaction and aimed to close as early as possible, with closing likely pushed into early 2027.
• Boston Scientific said it would provide more detail on the Penumbra transaction after closing.

Impact estimates